Finding suitable antigens for immunotherapy of myeloid malignancies, particularly acute myeloid leukemia (AML), is an urgent clinical need. Most AML candidate targets, including CD123, are co-expressed by hematopoietic stem and progenitor cells (HSCPs), with the subsequent risk of myelosuppression associated with myeloid cell-targeted chimeric antigen receptor (CAR) T therapy.
Radiopharm Theranostics Ltd. has been granted human research ethics committee (HREC) approval to commence a first-in-human phase I study in Australia for RAD-204, the company’s radiotherapeutic for patients with PD-L1-positive non-small-cell lung cancer (NSCLC).
The structures of the majority of PD-1/PD-L1 inhibitors currently in use are derived from the arylmethylamine/biphenyl scaffold. Researchers from Southern Medical University reported on the discovery and preclinical evaluation of a novel series of non-arylmethylamine-based PD-1/PD-L1 inhibitors for use in cancer immunotherapy.
Guangzhou Maxinovel Pharmaceuticals Co. Ltd. has described thienopyrimidine compounds acting as ALK, fibroblast growth factor receptor (FGFR) and high affinity nerve growth factor (TRK) inhibitors reported to be useful for the treatment of cancer, infections and psoriasis and inflammation.
Nammi Therapeutics Inc. has divulged prodrugs of Toll-like receptor (TLR) agonists and its self-assembled lipid nanoparticles reported to be useful for the treatment of cancer and immunological disorders.
Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Shanghai Ringene Biopharma Co. Ltd. has synthesized CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, hemolytic anemia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, sepsis, idiopathic thrombocytopenic purpura and ulcerative colitis, among others.
JS Innomed Holdings Ltd. has disclosed heterocyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.
Current therapies based on immune checkpoint blockade are effective and offer a valid option for treatment, but many patients develop either primary or acquired resistance to treatment. Previous research has shown that the deletion of protein tyrosine phosphatases PTPN2 and PTPN1 results in an increase in the sensitization of tumor cells and the promotion of antitumor immunity.
Protein-arginine deiminase type-4 (PAD4) protein contributes to the formation of neutrophil extranuclear traps (NETs), which in turn lead to tumor growth and cancer immune escape that favors metastatic disease. The expression of PAD4 in certain types of cells, such as hematopoietic stem cells, makes the strategy of PAD4 inhibition risky due to adverse side effects.
RSS
